|0.125 0 (0%)||12-05 12:33|
|Targets||6-month :||0.37||1-year :||0.41|
|Resists||First :||0.31||Second :||0.35|
|Supports||First :||0.25||Second :||0.21|
|MAs||MA(5) :||0.31||MA(20) :||0.31|
|MA(100) :||0.35||MA(250) :||0.34|
|MACD||MACD :||-0.1||Signal :||-0.1|
|%K %D||K(14,3) :||69.9||D(3) :||73.7|
|52-week||High :||0.6||Low :||0.07|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ EMMA ] has closed above bottom band by 37.8%. Bollinger Bands are 34.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||0.3 - 0.3||0.3 - 0.3|
|Low:||0.25 - 0.26||0.26 - 0.26|
|Close:||0.3 - 0.3||0.3 - 0.3|
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
Wed, 23 Aug 2023
Emmaus Life Sciences Reports Management Changes - PR Newswire
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||51 (M)|
|Shares Float||31 (M)|
|Held by Insiders||37.9 (%)|
|Held by Institutions||0 (%)|
|Shares Short||41 (K)|
|Shares Short P.Month||34 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||-0.69|
|Profit Margin||-57.8 %|
|Operating Margin||-35.9 %|
|Return on Assets (ttm)||-7.9 %|
|Return on Equity (ttm)||0 %|
|Qtrly Rev. Growth||96.4 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||0.36|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-5 (M)|
|Levered Free Cash Flow||4 (M)|
|Price to Book value||-0.44|
|Price to Sales||0.83|
|Price to Cash Flow||-3.02|
|Dividend Pay Date||2019-07-17|
|Ex-Dividend Date||Invalid DateTime.|